BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250715
DTEND;VALUE=DATE:20250718
DTSTAMP:20260515T065653
CREATED:20250409T111422Z
LAST-MODIFIED:20250411T115959Z
UID:40893-1752537600-1752796799@www.pharmajournalist.com
SUMMARY:5th Inner Ear Disorders Therapeutics Summit
DESCRIPTION:Building on recent breakthroughs in gene therapy\, 2025 is poised for major advancements in cell transplants\, gamma secretase inhibitors\, anti-inflammatory programs\, and more to address the growing unmet need for more transformative hearing loss treatments. \n \nWith an aging population and an urgent need to restore a greater spectrum of hearing abilities beyond the scope of current device-based interventions\, there has never been a more critical time for the field to unite and drive progress. \nCoined by industry as the only meeting of its kind\, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical\, translational\, and clinical bottlenecks\, the 5th Inner Ear Disorders Therapeutics Summit returns as your definitive forum to benchmark learnings from past failures and ignite renewed optimism into the hearing loss therapeutic landscape. \nWith pioneering insights from Regeneron\, Biogen\, Acousia\, Rinri\, Ting Therapeutics\, Lineage Cell Therapeutics\, Gateway and more\, join 50+ of your peers to: \n\nAdvance translatable models to recapitulate complex human inner ear pathophysiology\nDeepen knowledge of molecular and genetic pathways underlying age-related\, noise-induced\, and congenital hearing loss to uncover druggable pathways\nEvaluate clinical progress in gene therapy for restored hearing and decipher the journey to success in Phase III populations\nOvercome translational challenges of bringing advanced therapies\, including small molecule and cell-based approaches\, to the clinic\nUncover opportunities for drug-device combinations to enable precise drug delivery and enhance the hearing preservation capabilities of cochlear implants\nHear large pharma and investor perspectives on what must be demonstrated to de-risk business opportunities within the hearing disorders space\n\nJoin this unparalleled forum of biotech innovators\, pharma stakeholders\, medical device manufacturers\, and leading academics in a collaborative atmosphere to advance otoprotection\, hearing restoration\, and gene therapy R&D and transform the treatment of hearing loss. \nFind out more in our brochure: https://ter.li/22rawz
URL:http://www.pharmajournalist.com/event/5th-inner-ear-disorders-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR